Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Corcept Therapeutics Inc. News

    22,80 $ +2,66% +0,59 $
    In : 21,323 € | 22:00:00 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 529882
    ISIN: US2183521028
    US-Symbol: CORT
    Typ: Aktie

    Corcept Therapeutics Inc. News

    02.01.24 - PR Newswire
    Thinking about trading options or stock in Exxon Mobil, Amazon.com, Meta Platforms, Enterprise Products Partners, or Corcept Therapeutics?
    Thinking about trading options or stock in Exxon Mobil, Amazon.com, Meta Platforms, Enterprise Products Partners, or Corcept Therapeutics? PR Newswire
    30.12.22 - PR Newswire
    NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
    NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT PR Newswire
    27.01.22 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT PR Newswire
    17.01.22 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT PR Newswire
    06.01.22 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT PR Newswire
    13.12.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT PR Newswire
    19.11.20 - PR Newswire
    Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?
    Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group? PR Newswire
    29.09.20 - PR Newswire
    SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to Contact the Firm
    SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to ...
    11.04.19 - PR Newswire
    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To Contact The Firm
    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To ...
    21.03.19 - PR Newswire
    EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated -- CORT
    EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated -- CORT PR Newswire
    19.03.19 - PR Newswire
    CORT Class Action Alert: Hagens Berman Alerts Corcept Therapeutics (NASDAQ: CORT) Investors to Securities Class Action and May 13, 2019 Lead Plaintiff Deadline
    CORT Class Action Alert: Hagens Berman Alerts Corcept Therapeutics (NASDAQ: CORT) Investors to Securities Class Action and May 13, 2019 Lead Plaintiff Deadline PR Newswire
    18.03.19 - PR Newswire
    Corcept (CORT) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
    Corcept (CORT) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT PR Newswire
    15.03.19 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PR Newswire
    05.02.19 - PR Newswire
    Investor Alert: Kaplan Fox Investigates Corcept Therapeutics Incorporated
    Investor Alert: Kaplan Fox Investigates Corcept Therapeutics Incorporated PR Newswire
    20.12.17 - PR Newswire
    Interactive Brokers Group Set to Join S&P MidCap 400; Alarm.com Holdings and Corcept Therapeutics to Join S&P SmallCap 600
    Interactive Brokers Group Set to Join S&P MidCap 400; Alarm.com Holdings and Corcept Therapeutics to Join S&P SmallCap 600 PR Newswire
    02.11.09 - Aktiencheck
    Corcept Therapeutics kaufen - Global Biotech Investing
    Die Experten von "Global Biotech Investing" raten zum Kauf der Corcept Therapeutics-​Aktie . Die Biotech-​Gesellschaft habe bei Institutionellen 18 Mio. USD eingesammelt, wodurch ...
    30.04.07 - Aktiencheck
    Corcept Therapeutics vorsichtig abfischen - Global Insider Investing
    28.12.06 - Aktiencheck
    Corcept Therapeutics im Auge behalten - Global Insider Investing
    28.08.06 - Aktiencheck
    Corcept Therapeutics Downgrade - Merriman Curhan Ford & Co
    Rating-​Update: San Francisco (aktiencheck.de AG) - Die Analysten von Merriman Curhan Ford & Co stufen die Aktie von Corcept Therapeutics von "buy" auf "neutral" zurück. ...
    28.08.06 - Aktiencheck
    Corcept Therapeutics Downgrade - Thomas Weisel
    Rating-​Update: San Francisco (aktiencheck.de AG) - Die Analysten von Thomas Weisel stufen die Aktie von Corcept Therapeutics von "outperform" auf "peer perfrom" zurück. ...

    Newssuche

    Videos

    newspaper
    08:40 Uhr +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »